Suchergebnisse - "Maher, Elizabeth A"

PubPharm (93)

1

Author Correction : Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial

enthalten in: Nature medicine | 2024

von Mellinghoff, I. | Lu, M. | Wen, P. | +17

ErratumFor: Nat Med. 2023 Mar;29(3):615-622. - PMID 36823302

2

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma

enthalten in: The New England journal of medicine | 2023

von Mellinghoff, I. | van den Bent, M. | Blumenthal, D. | +119

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):737-738. - PMID 37460634

3

Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma : a randomized, perioperative phase 1 trial

enthalten in: Nature medicine | 2023

von Mellinghoff, I. | Lu, M. | Wen, P. | +17

ErratumIn: Nat Med. 2023 Jul 3;:. - PMID 37400643

4

Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas

enthalten in: Discover. Oncology | 2022

von Hsu, E. | Thomas, J. | Maher, E. | +6

5

Impact of CDKN2A/B, MTAP, and TERT Genetic Alterations on Survival in IDH Wild Type Glioblastomas

enthalten in: Discover oncology | 2022

von Hsu, E. | Thomas, J. | Maher, E. | +6

6

Optimization of spectrally selective 180° radiofrequency pulse timings in J-difference editing (MEGA) of lactate

enthalten in: Magnetic resonance in medicine | 2022

von Ganji, S. | An, Z. | Tiwari, V. | +4

7

Neutrophilia and post-radiation thrombocytopenia predict for poor prognosis in radiation-treated glioma patients

enthalten in: Frontiers in oncology | 2022

von Hsu, E. | Thomas, J. | Maher, E. | +7

8

Optimization of spectrally selective 180° radiofrequency pulse timings in J‐difference editing (MEGA) of lactate

enthalten in: Magnetic Resonance in Medicine | 2022

von Ganji, S. | An, Z. | Tiwari, V. | +4

9

Spectral fitting strategy to overcome the overlap between 2-hydroxyglutarate and lipid resonances at 2.25 ppm

enthalten in: Magnetic resonance in medicine | 2021

von Askari, P. | Dimitrov, I. | Ganji, S. | +8

10

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2021

von Mellinghoff, I. | Penas-Prado, M. | Peters, K. | +18

1
2
3
4
5
6
7
8
9
10
Nächster »
[10]